Usama Salem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Usama Salem has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Corey T. Jensen
Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications - Khaled M. Elsayes
The University of Texas MD Anderson Cancer Center, Houston, USA
3 shared publications - Nir Stanietzky
The University of Texas, MD Anderson Cancer Center, Department of Abdominal Imaging, Texas, USA
3 shared publications - Ajaykumar C. Morani
The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications - Muhammad O. Awiwi
Department of Radiology, The University of Texas Health Science Center at Houston, Houston, Tex
2 shared publications Randy Ernst
2 shared publications
Latest Publications
- Open Access
- 10 July 2024
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 31 (4) , 285-294
Tumor-like conditions that mimic liver tumors
Tumor-like conditions that mimic liver tumors - Diagnostic and Interventional Radiology
- 10 July 2024
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 31 (4) , 285-294
Open AccessTumor-like conditions that mimic liver tumors
Tumor-like conditions that mimic liver tumors - Diagnostic and Interventional Radiology
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (12) , e230112
MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer
Prostate cancer may recur several years after definitive treatment, such as prostatectomy or radiation therapy. A rise in serum prostate-specific antigen (PSA) level is the first sign of disease recurrence, and this is termed biochemical recurrence. Patients with biochemical recurrence have worse survival outcomes. Radiologic localization of recurrent disease helps in directing patient management, which may vary from active surveillance to salvage radiation therapy, androgen-deprivation therapy, or other forms of systemic and local therapy. The likelihood of detecting the site of recurrence increases with higher serum PSA level. MRI provides optimal diagnostic performance for evaluation of the prostatectomy bed. Prostate-specific membrane antigen (PSMA) PET radiotracers currently approved by the U.S. Food and Drug Administration demonstrate physiologic urinary excretion, which can obscure recurrence at the vesicourethral junction. However, MRI and PSMA PET/CT have comparable diagnostic performance for evaluation of local recurrence after external-beam radiation therapy or brachytherapy. PSMA PET/CT outperforms MRI in identifying recurrence involving the lymph nodes and bones. Caveats for use of both PSMA PET/CT and MRI do exist and may cause false-positive or false-negative results. Hence, these techniques have complementary roles and should be interpreted in conjunction with each other, taking the patient history and results of any additional prior imaging studies into account. Novel PSMA agents at various stages of investigation are being developed, and preliminary data show promising results; these agents may revolutionize the landscape of prostate cancer recurrence imaging in the future. ©RSNA, 2023 Quiz questions for this article are available through the Online Learning Center. See the invited commentary by Turkbey in this issue. The slide presentation from the RSNA Annual Meeting is available for this article.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (12) , e230112
MRI and PSMA PET/CT of Biochemical Recurrence of Prostate Cancer
Prostate cancer may recur several years after definitive treatment, such as prostatectomy or radiation therapy. A rise in serum prostate-specific antigen (PSA) level is the first sign of disease recurrence, and this is termed biochemical recurrence. Patients with biochemical recurrence have worse survival outcomes. Radiologic localization of recurrent disease helps in directing patient management, which may vary from active surveillance to salvage radiation therapy, androgen-deprivation therapy, or other forms of systemic and local therapy. The likelihood of detecting the site of recurrence increases with higher serum PSA level. MRI provides optimal diagnostic performance for evaluation of the prostatectomy bed. Prostate-specific membrane antigen (PSMA) PET radiotracers currently approved by the U.S. Food and Drug Administration demonstrate physiologic urinary excretion, which can obscure recurrence at the vesicourethral junction. However, MRI and PSMA PET/CT have comparable diagnostic performance for evaluation of local recurrence after external-beam radiation therapy or brachytherapy. PSMA PET/CT outperforms MRI in identifying recurrence involving the lymph nodes and bones. Caveats for use of both PSMA PET/CT and MRI do exist and may cause false-positive or false-negative results. Hence, these techniques have complementary roles and should be interpreted in conjunction with each other, taking the patient history and results of any additional prior imaging studies into account. Novel PSMA agents at various stages of investigation are being developed, and preliminary data show promising results; these agents may revolutionize the landscape of prostate cancer recurrence imaging in the future. ©RSNA, 2023 Quiz questions for this article are available through the Online Learning Center. See the invited commentary by Turkbey in this issue. The slide presentation from the RSNA Annual Meeting is available for this article.
- 3 August 2023
- Published by International Society for Magnetic Resonance in Medicine (ISMRM)
3D T2-Weighted Rectal Cancer Imaging using a 3D Fast Spin Echo Sequence with Deep Learning Reconstruction
Multiplanar high resolution T2-weighted (T2W) imaging with a 2D fast spin echo (FSE) sequence is currently an essential component of rectal cancer MRI. In this work, we performed T2W imaging of rectal cancer with a 3D FSE sequence and evaluated the quality and potential clinical value of the images after applying a postprocessing deep learning reconstruction (DLR) algorithm. We found that DLR images are non-inferior to conventional images and there are fair-moderate inter-reader agreements in a large majority of the categories evaluated for image quality and clinical usefulness.
- 3 August 2023
- Published by International Society for Magnetic Resonance in Medicine (ISMRM)
3D T2-Weighted Rectal Cancer Imaging using a 3D Fast Spin Echo Sequence with Deep Learning Reconstruction
Multiplanar high resolution T2-weighted (T2W) imaging with a 2D fast spin echo (FSE) sequence is currently an essential component of rectal cancer MRI. In this work, we performed T2W imaging of rectal cancer with a 3D FSE sequence and evaluated the quality and potential clinical value of the images after applying a postprocessing deep learning reconstruction (DLR) algorithm. We found that DLR images are non-inferior to conventional images and there are fair-moderate inter-reader agreements in a large majority of the categories evaluated for image quality and clinical usefulness.
- 1 April 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (4) , e220135
Restaging MRI of Rectal Adenocarcinoma after Neoadjuvant Chemoradiotherapy: Imaging Findings and Potential Pitfalls
Rectal adenocarcinoma constitutes about one-third of all colorectal adenocarcinoma cases. Rectal MRI has become mandatory for evaluation of patients newly diagnosed with rectal cancer because it can help accurately stage the disease, impact the choice to give neoadjuvant therapy or proceed with up-front surgery, and even direct surgical dissection planes. Better understanding of neoadjuvant chemoradiotherapy effects on rectal tumors and recognition that up to 30% of patients can have a pathologic complete response have opened the door for the nonsurgical "watch-and-wait" management approach for rectal adenocarcinoma. Candidates for this organ-preserving approach should have no evidence of malignancy on all three components of response assessment after neoadjuvant therapy (ie, digital rectal examination, endoscopy, and rectal MRI). Hence, rectal MRI again has a major role in directing patient management and possibly sparing patients from unnecessary surgical morbidity. In this article, the authors discuss the indications for neoadjuvant therapy in management of patients with rectal adenocarcinoma, describe expected imaging appearances of rectal adenocarcinoma after completion of neoadjuvant therapy, and outline the MRI tumor regression grading system. Since pelvic sidewall lymph node dissection is associated with a high risk of permanent genitourinary dysfunction, it is performed for only selected patients who have radiologic evidence of sidewall lymph node involvement. Therefore, the authors review the relevant lymphatic compartments of the pelvis and describe lymph node criteria for determining locoregional nodal spread. Finally, the authors discuss limitations of rectal MRI, describe several potential interpretation pitfalls after neoadjuvant therapy, and emphasize how these pitfalls may be avoided. © RSNA, 2023 Quiz questions for this article are available in the supplemental material.
- 1 April 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (4) , e220135
Restaging MRI of Rectal Adenocarcinoma after Neoadjuvant Chemoradiotherapy: Imaging Findings and Potential Pitfalls
Rectal adenocarcinoma constitutes about one-third of all colorectal adenocarcinoma cases. Rectal MRI has become mandatory for evaluation of patients newly diagnosed with rectal cancer because it can help accurately stage the disease, impact the choice to give neoadjuvant therapy or proceed with up-front surgery, and even direct surgical dissection planes. Better understanding of neoadjuvant chemoradiotherapy effects on rectal tumors and recognition that up to 30% of patients can have a pathologic complete response have opened the door for the nonsurgical "watch-and-wait" management approach for rectal adenocarcinoma. Candidates for this organ-preserving approach should have no evidence of malignancy on all three components of response assessment after neoadjuvant therapy (ie, digital rectal examination, endoscopy, and rectal MRI). Hence, rectal MRI again has a major role in directing patient management and possibly sparing patients from unnecessary surgical morbidity. In this article, the authors discuss the indications for neoadjuvant therapy in management of patients with rectal adenocarcinoma, describe expected imaging appearances of rectal adenocarcinoma after completion of neoadjuvant therapy, and outline the MRI tumor regression grading system. Since pelvic sidewall lymph node dissection is associated with a high risk of permanent genitourinary dysfunction, it is performed for only selected patients who have radiologic evidence of sidewall lymph node involvement. Therefore, the authors review the relevant lymphatic compartments of the pelvis and describe lymph node criteria for determining locoregional nodal spread. Finally, the authors discuss limitations of rectal MRI, describe several potential interpretation pitfalls after neoadjuvant therapy, and emphasize how these pitfalls may be avoided. © RSNA, 2023 Quiz questions for this article are available in the supplemental material.
- 24 November 2022
- Published by Springer Nature
- p. 417-439
Imaging Response Evaluation
- 11 January 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 303 (1) , 90-98
Reduced-Dose Deep Learning Reconstruction for Abdominal CT of Liver Metastases
At 65% reduced radiation dose, deep learning image reconstruction improved CT image quality with robust denoising but had inferior lesion characterization and inferior lesion detection for small li... Background Assessment of liver lesions is constrained as CT radiation doses are lowered; evidence suggests deep learning reconstructions mitigate such effects. Purpose To evaluate liver metastases ...
- 11 January 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 303 (1) , 90-98
Reduced-Dose Deep Learning Reconstruction for Abdominal CT of Liver Metastases
At 65% reduced radiation dose, deep learning image reconstruction improved CT image quality with robust denoising but had inferior lesion characterization and inferior lesion detection for small li... Background Assessment of liver lesions is constrained as CT radiation doses are lowered; evidence suggests deep learning reconstructions mitigate such effects. Purpose To evaluate liver metastases ...
- Open Access
Mastocytosis—A Review of Disease Spectrum with Imaging Correlation
Mastocytosis is a rare disorder due to the abnormal proliferation of clonal mast cells. Mast cells exist in most tissues, mature in situ from hematopoietic stem cells and develop unique characteristics of local effector cells. Mastocytosis develops by activation mutation of the KIT surface receptor which is involved in the proliferation of a number of cell lines such as mast cells, germ cells, melanocytes, and hematopoietic cells. It manifests as two main categories: cutaneous mastocytosis and systemic mastocytosis. Imaging can play an important role in detection and characterization of the disease manifestation, not only by radiography and bone scans, but also magnetic resonance imaging and computed tomography, which can be more sensitive in the assessment of distinctive disease patterns. Radiologists should be aware of various appearances of this disease to better facilitate diagnosis and patient management. Accordingly, this review will discuss the clinical presentation, pathophysiology, and role of imaging in detection and extent estimation of the systemic involvement of the disease, in addition to demonstration of appearance on varying imaging modalities. Familiarity with the potential imaging findings associated with mastocytosis can aid in early disease diagnosis and classification and accordingly can lead directing further work up and better management.
Open AccessMastocytosis—A Review of Disease Spectrum with Imaging Correlation
Mastocytosis is a rare disorder due to the abnormal proliferation of clonal mast cells. Mast cells exist in most tissues, mature in situ from hematopoietic stem cells and develop unique characteristics of local effector cells. Mastocytosis develops by activation mutation of the KIT surface receptor which is involved in the proliferation of a number of cell lines such as mast cells, germ cells, melanocytes, and hematopoietic cells. It manifests as two main categories: cutaneous mastocytosis and systemic mastocytosis. Imaging can play an important role in detection and characterization of the disease manifestation, not only by radiography and bone scans, but also magnetic resonance imaging and computed tomography, which can be more sensitive in the assessment of distinctive disease patterns. Radiologists should be aware of various appearances of this disease to better facilitate diagnosis and patient management. Accordingly, this review will discuss the clinical presentation, pathophysiology, and role of imaging in detection and extent estimation of the systemic involvement of the disease, in addition to demonstration of appearance on varying imaging modalities. Familiarity with the potential imaging findings associated with mastocytosis can aid in early disease diagnosis and classification and accordingly can lead directing further work up and better management.
- Open Access
Oncologic Imaging of the Lymphatic System: Current Perspective with Multi-Modality Imaging and New Horizon
The lymphatic system is an anatomically complex vascular network that is responsible for interstitial fluid homeostasis, transport of large interstitial particles and cells, immunity, and lipid absorption in the gastrointestinal tract. This network of specially adapted vessels and lymphoid tissue provides a major pathway for metastatic spread. Many malignancies produce vascular endothelial factors that induce tumoral and peritumoral lymphangiogenesis, increasing the likelihood for lymphatic spread. Radiologic evaluation for disease staging is the cornerstone of oncologic patient treatment and management. Multiple imaging modalities are available to access both local and distant metastasis. In this manuscript, we review the anatomy, physiology, and imaging of the lymphatic system.
Open AccessOncologic Imaging of the Lymphatic System: Current Perspective with Multi-Modality Imaging and New Horizon
The lymphatic system is an anatomically complex vascular network that is responsible for interstitial fluid homeostasis, transport of large interstitial particles and cells, immunity, and lipid absorption in the gastrointestinal tract. This network of specially adapted vessels and lymphoid tissue provides a major pathway for metastatic spread. Many malignancies produce vascular endothelial factors that induce tumoral and peritumoral lymphangiogenesis, increasing the likelihood for lymphatic spread. Radiologic evaluation for disease staging is the cornerstone of oncologic patient treatment and management. Multiple imaging modalities are available to access both local and distant metastasis. In this manuscript, we review the anatomy, physiology, and imaging of the lymphatic system.
- Open Access
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (15) , 2892-2898
18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone
Objective: The existing literature of 18 F-FDG PET/CT in Ewing sarcoma investigates mixed populations of patients with both soft tissue and bone primary tumors. The aim of our study was to evaluate whether the maximum standardized uptake value (SUVmax) obtained with 18F-FDG PET/CT before and after induction chemotherapy can be used as an indicator of survival in patients with Ewing sarcoma originating exclusively in the skeleton.
- 1 January 2017
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (15) , 2892-2898
Open Access18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone
Objective: The existing literature of 18 F-FDG PET/CT in Ewing sarcoma investigates mixed populations of patients with both soft tissue and bone primary tumors. The aim of our study was to evaluate whether the maximum standardized uptake value (SUVmax) obtained with 18F-FDG PET/CT before and after induction chemotherapy can be used as an indicator of survival in patients with Ewing sarcoma originating exclusively in the skeleton.